What is Zacks Research's Estimate for Hologic Q4 Earnings?

Hologic, Inc. (NASDAQ:HOLX - Free Report) - Analysts at Zacks Research dropped their Q4 2025 EPS estimates for Hologic in a report issued on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $1.12 for the quarter, down from their prior estimate of $1.13. The consensus estimate for Hologic's current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic's FY2027 earnings at $4.97 EPS.

Several other equities analysts have also issued reports on the stock. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Morgan Stanley reduced their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Royal Bank of Canada decreased their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Jefferies Financial Group assumed coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $84.62.

Remove Ads

Hologic Stock Up 1.4 %

Shares of Hologic stock traded up $0.84 on Monday, reaching $62.32. The stock had a trading volume of 1,303,646 shares, compared to its average volume of 1,751,573. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.98 billion, a P/E ratio of 19.66, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a 50 day moving average price of $65.56 and a 200 day moving average price of $73.57. Hologic has a 1 year low of $60.34 and a 1 year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Swedbank AB increased its holdings in shares of Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock valued at $157,788,000 after purchasing an additional 306,562 shares in the last quarter. Empowered Funds LLC increased its holdings in Hologic by 8.8% in the third quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider's stock valued at $294,000 after buying an additional 291 shares in the last quarter. Pathstone Holdings LLC raised its position in shares of Hologic by 7.7% in the third quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider's stock worth $2,422,000 after acquiring an additional 2,121 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Hologic by 13.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 37,161 shares of the medical equipment provider's stock worth $3,027,000 after acquiring an additional 4,504 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Hologic during the 3rd quarter valued at about $2,350,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.